Αρχική World News EMA Recommends Granting a Marketing Authorisation for Senaparib World News EMA Recommends Granting a Marketing Authorisation for Senaparib Από Ogkologos - 15 Οκτωβρίου, 2026 379 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the maintenance treatment of advanced epithelial ovarian, Fallopian tube and primary peritoneal cancer Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... 4 Ιουλίου, 2025 Study Clarifies Timing of Immunotherapy for Advanced Bladder Cancer 24 Ιουνίου, 2020 Developing Biomarkers for Immunotherapy: A Conversation with Drs. Magdalena Thurin and... 27 Ιουλίου, 2018 2021 ASCO Annual Meeting Research Round Up: New Research in Gynecologic... 16 Αυγούστου, 2021 Φόρτωση περισσοτέρων HOT NEWS Poziotinib Shows Promising Antitumour Activity in Patients with HER2 Exon 20... ESMO Shares Recommendations to Support Cancer Research and Clinical Trials in... Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling... Rise in Brain Metastases Detected in Patients with Stage IV NSCLC...